Genomic studies indicate a novel combination therapy for follicular lymphoma

Abstract

Follicular lymphoma (FL) is an incurable form of B-cell lymphoma. Genomic alterations that inactivate RB signaling are surprisingly common in indolent FL. We show that FLs that are positive for phosphorylated RB respond to dual CDK4/BCL2 inhibition. Our results imply that RB phosphorylation identifies patients likely to benefit from such dual intervention.

Keywords

• bcl2
• cell cycle
• follicular lymphoma
• therapy